KAAPA Biotech, headquartered in Karjalohja, Finland, develops high-purity functional mushroom extracts intended for use in wellness, nutrition, and supplement products. The company operates a fully vertically integrated model through its KAAPA Forest, KAAPA Mushrooms, and Nordic Mushrooms divisions, controlling everything from sustainable cultivation to proprietary extraction. Its network is reported to be the world’s largest chaga cultivation operation and has been expanded with new facilities in Paimio and Salo to boost capacity and research capabilities. KAAPA targets species such as lion’s mane, chaga, cordyceps, and reishi, quantifying their unique bioactive compounds to standardise potency and efficacy. Proprietary extraction processes deliver consistent concentrations of hericenones, betulinic acid, triterpenoids, and other actives that support cognitive health, immunity, and longevity. The firm is running clinical studies, including on chaga’s antioxidant and healthy-ageing potential, to underpin its health claims with reproducible data. With the fresh capital, KAAPA plans to expand production, deepen vertical integration, and advance its clinical research pipeline.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025